Get the Stockscreener App
145.70
2.24%
3.19
Pre-market:
148.64
2.94
+2.02%
Illumina Inc stock is traded at $145.70, with a volume of 2.83M.
It is up +2.24% in the last 24 hours and up +20.48% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$142.51
Open:
$143.5
24h Volume:
2.83M
Relative Volume:
1.58
Market Cap:
$22.04B
Revenue:
$4.39B
Net Income/Loss:
$853.00M
P/E Ratio:
26.44
EPS:
5.5097
Net Cash Flow:
$556.00M
1W Performance:
+4.77%
1M Performance:
+20.48%
6M Performance:
+19.45%
1Y Performance:
+78.62%
1-Day Range:
$142.36
$146.75
1-Week Range:
$134.67
$146.75
52-Week Range:
$77.50
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
145.70 | 21.56B | 4.39B | 853.00M | 556.00M | 5.5097 |
TMO
Thermo Fisher Scientific Inc
|
459.30 | 168.20B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
166.26 | 117.86B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
533.92 | 41.97B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
352.21 | 34.17B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.90 | 31.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
The Bull Case For Illumina (ILMN) Could Change Following Upgraded 2026 Outlook And Major BuybackLearn Why - simplywall.st
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina stock (US4523271090): Analyst consensus shifts to Hold amid mixed signals - AD HOC NEWS
Illumina Inc. stock (US4523271090): Latest developments and business overview - AD HOC NEWS
SomaLogic stock (US82489T1043): Completed $350M sale to Illumina - AD HOC NEWS
Illumina Innovation Fund Iii, L.p. Net Worth (2026) - GuruFocus
Corvex funds (NASDAQ: ILMN) exercise Illumina equity swaps, retain large position - Stock Titan
How Illumina employees work to move healthcare toward precision medicine - Illumina
NovaSeq X software update v1.4 improves data quality and customer usability - Illumina
Global Personalized Medicine to Transform Modern Healthcare and Cross USD 1 Trillion by 2034 | DelveInsight - GlobeNewswire Inc.
Illumina stock (US4523271090): Q1 earnings beat lifts shares 8% YTD - AD HOC NEWS
We Think That There Are Issues Underlying Illumina's (NASDAQ:ILMN) Earnings - simplywall.st
Avoiding Lag: Real-Time Signals in (ILMN) Movement - Stock Traders Daily
HPE, Charles Schwab, Zomedica, Illumina, Circle Insider Shake-Up - TipRanks
Illumina Inc. stock (US4523271090): Earnings beat and momentum lift shares - AD HOC NEWS
Uber, Exxon Mobil, Illumina, Diamondback Energy: CNBC's 'Final Trades' - MSN
Dna Forensic Market Is Booming So Rapidly | Agilent Technologies, Illumina, Bio-Rad Laboratories - openPR.com
Illumina Inc. Stock (US4523271090): Analyst Ratings and Price Targets in Focus - AD HOC NEWS
Illumina SVP Jakob Wedel Christensen sells $97,328 in stock - Investing.com UK
Illumina SVP Jakob Wedel Christensen sells $97,328 in stock By Investing.com - Investing.com Australia
Illumina (NASDAQ: ILMN) SVP logs 700-share sale and 233-share tax withholding - Stock Titan
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina Patent Lawsuit Targets BillionToOne Prenatal Tests (1) - Bloomberg Law News
Illumina showcases multi-omics potential to advance precision medicine in India - Indian Pharma Post
Next-Generation Genome Mapping Market is Thriving Worldwide | - openPR.com
Microfluidics Market Competitive Analysis to 2031 | Illumina, Inc, microfluidic ChipShop GmbH, Danaher etc. - openPR.com
Illumina Shareholder Action Reminder - TMX Newsfile
[144] ILLUMINA, INC. SEC Filing - Stock Titan
ILMN Stock Price, Quote & Chart | ILLUMINA INC (NASDAQ:ILMN) - ChartMill
Whole Exome Sequencing Market key players 2024-2031: Illumina, Inc., Centogene AG, Eurofins Scientific etc - openPR.com
Assessing Illumina (ILMN) Valuation After Earnings Beat Guidance Hike And Expanded Buyback - Yahoo Finance
Illumina Shareholder Alert - TMX Newsfile
Here's Why Illumina (ILMN) is a Strong Growth Stock - Yahoo Finance
Epigenetics Market is expected to Hit US$ 7.10 Billion by 2033 | - openPR.com
Illumina, Inc. Q1 2026 Financial Report: Earnings, Revenue, Risk Factors & Forward-Looking Statements 18 24 37 - Minichart
Final Trades: Uber, Exxon, Illumina and Diamondback Energy - CNBC
Illumina Partners with Florida State University Lab for Rare Disease Genome Sequencing - Clinical Lab Products
Genomics Market size is anticipated to reach US$ 83.61 billion - openPR.com
Illumina, Inc. (ILMN) Stock Analysis: Exploring Its 33.82% Return On Equity - DirectorsTalk Interviews
Illumina (ILMN) Q1 2026 Earnings: Revenue Beat and Raised GuidanceNews and Statistics - IndexBox
Illumina, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ILMN) 2026-05-03 - Seeking Alpha
ILMN Q1 Deep Dive: Clinical Sequencing Fuels Growth as NovaSeq X Demand Surges - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM) - The Globe and Mail
Illumina revenue up 4.8% to USD 1.09B in Q1 2026 - Medical Buyer
Jennison Associates LLC Has $26.21 Million Stock Position in Illumina, Inc. $ILMN - MarketBeat
MSN Money - MSN
Illumina earnings loom as investors seek clarity on 2026 outlook By Investing.com - Investing.com Nigeria
[10-Q] ILLUMINA, INC. Quarterly Earnings Report - Stock Titan
Illumina jumps 7.1% as Q1 results top expectations and full-year outlook rises - Quiver Quantitative
Illumina (NASDAQ:ILMN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Here’s Why Illumina Stock Could Deliver 8% Annual Returns Through 2028 - TIKR.com
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):